Derma Sciences, Inc. (Nasdaq: DSCI), a medical device and pharmaceutical company focused on advanced wound care, announces the launch of a new video series library within the Company’s eLearning Portal website. The series consists of eight videos including Derma Sciences Commitment to Advanced Wound Care, as well as videos about the Company’s leading products; MEDIHONEY ®, XTRASORB ®, BIOGUARD ®, and ALGICELL ® Ag.

Available at, the eLearning Portal is designed to provide clinicians and the Company’s growing sales force with valuable educational programs to ensure they are kept abreast of the latest information concerning the Company’s line of advanced wound care products. The new video series will provide clinicians with detailed product overviews as well as information for use in clinical applications.

Commenting on the new video series, Derma Sciences CEO Ed Quilty said, “When we launched the eLearning Portal at the beginning of 2011, our goal was to bring current information to health care professionals and clinicians striving to deliver the highest quality care to patients with wounds and burns. These new videos will help keep our customers current on the benefits and options within our best-in-class wound management product line. Facilitating top-quality patient care remains our highest priority.”

In addition to the video series, the eLearning Portal contains both new and aggregated content from webinars on such topics as wound debridement, the use of MEDIHONEY ® on stalled wounds and those with atypical etiologies, and the benefits of super absorbent polymer technology in moist wound dressings. New webinars are added approximately every six weeks. The Portal also aggregates the considerable number of abstracts, articles and peer-reviewed clinical posters on MEDIHONEY ®, as well as broadcast media coverage about the Company’s products. Additionally, extensive product literature on MEDIHONEY ®, XTRASORB®, ALGICELL ® Ag, and BIOGUARD ® are available for download. Clinicians also can request product samples directly from the Portal.

About Derma Sciences, Inc.

Derma Sciences is a medical technology company focused on three segments of the wound care marketplace, traditional dressings, advanced wound care dressings, and pharmaceutical wound care products. Its MEDIHONEY® product is the leading brand of honey-based dressings for the management of wounds and burns. The product has been shown to be effective in a variety of indications, and was the focus of a positive large-scale, randomized controlled trial involving 108 subjects with leg ulcers. Other novel products introduced into the $14 billion global wound care market include XTRASORB® for better management of wound exudate, and BIOGUARD® for infection prevention. Derma Sciences has successfully completed a Phase 2 clinical trial in diabetic foot ulcer healing with DSC127, a novel pharmaceutical drug under development for accelerated wound healing and scar reduction. The company is in the process of preparing for Phase III pivotal studies. For more information please visit

Forward-Looking Statements

Statements contained in this news release that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the generality of the foregoing, words such as "may," "will," "expect," "believe," "anticipate," "intend," "could," "estimate" or "continue" are intended to identify forward-looking statements. Readers are cautioned that certain important factors may affect the Company's actual results and could cause such results to differ materially from any forward-looking statements that may be made in this news release or that are otherwise made by or on behalf of the Company. Factors that may affect the Company's results include, but are not limited to, product demand, market acceptance, impact of competitive products and prices, product development, completion of an acquisition, commercialization or technological difficulties, the success or failure of negotiations and trade, legal, social and economic risks. Additional factors that could cause or contribute to differences between the Company's actual results and forward-looking statements include but are not limited to, those discussed in the Company's filings with the U.S. Securities and Exchange Commission.

Copyright Business Wire 2010